Amorphous Solid Dispersion for Stable Oral P2X4 Antagonists

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The present compound, which acts as a P2X4 receptor antagonist, has poor water solubility, leading to inadequate in vivo absorbability when administered orally, and existing methods to improve solubility, such as micronization and solid dispersions, face stability issues during long-term storage.

Innovation Solution

A solid dispersion is formed with specific polymers like hydroxypropylmethylcellulose (HPMC) and sodium lauryl sulfate (SLS) to enhance the in vivo absorbability of the compound, maintaining its amorphous state and stability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If the compound is administered orally to improve in vivo absorbability, then the therapeutic effectiveness can be enhanced, but the poor water solubility of the compound limits its absorbability

Engineering Contradiction:
Improvein vivo absorbabilityVSAvoidwater solubility
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent changes the physical state parameter of the compound from crystalline to amorphous form. This parameter change dramatically improves water solubility and in vivo absorbability while maintaining the compound's pharmacological activity as a P2X4 receptor antagonist

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite material system consisting of the amorphous compound combined with specific polymers (hydroxypropylmethylcellulose, ethyl cellulose, or carboxymethyl cellulose). This composite structure maintains the amorphous state during storage and enhances both solubility and stability

Inventive Principle:
Principle #40Composite materials

2Quantity of substance

If the compound is converted to amorphous state to improve solubility, then in vivo absorbability is enhanced, but the amorphous state is unstable in the presence of moisture during long-term storage

Engineering Contradiction:
ImprovesolubilityVSAvoidstorage stability
Core Design Contradiction:
Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The patent introduces polymers (hydroxypropylmethylcellulose, ethyl cellulose, or carboxymethyl cellulose) as intermediary substances that interact with the amorphous compound. These polymers act as stabilizing agents that prevent moisture-induced crystallization while maintaining the amorphous state, thus resolving the contradiction between solubility enhancement and storage stability

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent creates a protective environment around the amorphous compound using hydrophobic polymers that exclude moisture. This inert-like environment prevents the amorphous compound from transitioning to crystalline form during long-term storage, maintaining both solubility and stability

Inventive Principle:
Principle #39Inert atmosphere (Inert environment)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solid dispersion significantly improves the oral absorbability of the P2X4 receptor antagonist, ensuring stable and effective delivery of the compound over time.

Implementation Method 1

it is necessary to convert the poorly soluble compounds into an amorphous state

Methodology Applied
Scientific EffectAmorphous state: Metastability

Implementation Method 2

the poorly soluble compound may transition from an amorphous state to a crystalline state during long-term storage

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Data Source

PatentEP4670720A1Solid dispersion of compound having p2x4 receptor antagonism
Publication Date: 2025.12.31 NIPPON CHEMIPHAR CO LTD
  • EP4670720A1 patent drawingFigure 1
  • EP4670720A1 patent drawingFigure 1
  • EP4670720A1 patent drawingFigure 2

AI summary

The present invention provides a solid dispersion comprising a compound represented by a general formula (I) or (II), or a pharmacologically acceptable salt thereof: or